[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368164-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-368164-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","cancer-incidence-and-the-influence-of-immunosuppressive-agents-in-korean-patients-with-systemic-lupus-erythematosus-a-retrospective-cohort-study","Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus - a retrospective cohort study","","Investigates cancer incidence and the potential influence of immunosuppressive agents in Korean systemic lupus erythematosus (SLE) patients. A retrospective cohort analysis used Korea Healthcare Bigdata Linked Platform data linking cancer registry and insurance records from 2008–2017. Incidence rates per 10,000 person-years were computed for site-specific cancers using ICD-O-3 codes, and multivariable logistic regression assessed associations. Among 10,013 mostly female patients, 368 developed cancer; no statistically significant association was found for immunosuppressive agents.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-incidence-and-the-influence-of-immunosuppressive-agents-in-korean-patients-with-systemic-lupus-erythematosus-a-retrospective-cohort-study/368164/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-incidence-and-the-influence-of-immunosuppressive-agents-in-korean-patients-with-systemic-lupus-erythematosus-a-retrospective-cohort-study/368164.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of this study?","Question",{"text":63,"@type":64},"To investigate cancer incidence and the potential influence of immunosuppressive agents in Korean SLE patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and methods were used?",{"text":68,"@type":64},"A retrospective analysis used linked national databases (2008–2017). Cancer incidence rates per 10,000 person-years were calculated with ICD-O-3 codes, and multivariable logistic regression tested associations with immunosuppressive agents.",{"name":70,"@type":61,"acceptedAnswer":71},"Did immunosuppressive agents significantly increase cancer development in SLE patients?",{"text":72,"@type":64},"No. The study found no statistically significant association (Odds Ratio 1.03, 95% CI 0.80–1.34).",{"name":74,"@type":61,"acceptedAnswer":75},"Which cancers were most prevalent and how were cancers staged?",{"text":76,"@type":64},"The most prevalent cancers by incidence rate were thyroid, breast, stomach, colorectal, and cervical. About half (50.8%) of SLE patients diagnosed with cancer were at the localized SEER stage.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},368164,1790386453,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Cho et al. Arthritis Research & Therapy (2025) 27:14 [https://doi.org/10.1186/s13075-025-03482-2](https://doi.org/10.1186/s13075-025-03482-2)  \nArthritis Research & Therapy  \n RESEARCH Open Access  \nCancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus:  \na retrospective cohort study  \nSoo-Kyung Cho1,2†, Jung-Yong Han 1,2†, Yena Jeon3, Seung-Hun You4, Sun-Young Jung4, Eun Jin Jang5 and Yoon-Kyoung Sung1,2*  \nAbstract  \nBackground To investigate cancer incidence and the potential influence of immunosuppressive agents in Korean systemic lupus erythematosus (SLE) patients.  \nMethods We conducted a retrospective analysis utilizing data from the Korea Healthcare Bigdata Linked Platform, which integrated the National Central Cancer Registry and National Health Insurance Service databases covering the period 2008–2017. Incidence rates (IRs) per 10,000 person-years (PYs) for site-specific cancers of SLE patients were calculated using ICD-O-3 codes. Multivariable logistic regression analysis was utilized to assess the association between immunosuppressive agents and cancer development in SLE patients.  \nResults A total of 10,013 predominantly female (91%) Korean SLE patients with a mean age of 36.9 ± 15.2 years were included. During a follow-up of 62,268 .5 PYs, 368 patients developed cancer. The IRs per 10,000 PYs for total, solid, and hematologic cancers were 59 . 07, 54 . 09, and 5 . 78, respectively. The most prevalent cancers (measured in IRs per 10,000 PYs) were thyroid (17 . 01, 95% CI 13.78–20. 25), breast (8 . 67, 95% CI 6.36–10. 98), stomach (4 .49, 95% CI 2.83–6. 16), colorectal (4 . 17, 95% CI 2.57–5. 78), and cervical (3 . 85, 95% CI 2 .31–5. 39) . Approximately half (50 . 8%) of SLE patients with cancer were diagnosed at the localized Surveillance, Epidemiology, and End Results (SEER) stage. No statistically significant association was found between immunosuppressive agents and cancer development (Odds Ratio 1. 03, 95% CI 0.80–1. 34) .  \nConclusion Our study shows that Korean SLE patients using immunosuppressive agents are not significantly more likely to develop cancer. Further research with extended observation is warranted to corroborate these findings. Keywords Systemic lupus erythematosus, Cancer, Incidence rate, Immunosuppressive agents  \n†Soo-Kyung Cho and Jung-Yong Han contributed equally as co-first authors.  \n*Correspondence: Yoon-Kyoung Sung [sungyk@hanyang.ac.kr](sungyk@hanyang.ac.kr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nCho et al. Arthritis Research & Therapy (2025) 27:14  \nIntroduction  \nSystemic lupus erythematosus (SLE) is a systemic autoimmune disease marked by chronic inflammation, often associated with comorbidities that contribute to increased mortality [1]. Cancer ranks ","cbCaitR5LYoYTWcx","https://ap.wps.com/l/cbCaitR5LYoYTWcx","pdf",892865,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## SLE and cancer risk\n## Medication-related risk factors","[{\"question\":\"What was the purpose of this study?\",\"answer\":\"To investigate cancer incidence and the potential influence of immunosuppressive agents in Korean SLE patients.\"},{\"question\":\"What data and methods were used?\",\"answer\":\"A retrospective analysis used linked national databases (2008–2017). Cancer incidence rates per 10,000 person-years were calculated with ICD-O-3 codes, and multivariable logistic regression tested associations with immunosuppressive agents.\"},{\"question\":\"Did immunosuppressive agents significantly increase cancer development in SLE patients?\",\"answer\":\"No. The study found no statistically significant association (Odds Ratio 1.03, 95% CI 0.80–1.34).\"},{\"question\":\"Which cancers were most prevalent and how were cancers staged?\",\"answer\":\"The most prevalent cancers by incidence rate were thyroid, breast, stomach, colorectal, and cervical. About half (50.8%) of SLE patients diagnosed with cancer were at the localized SEER stage.\"}]","Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus - a retrospective cohort study | PDF",1790175372,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4364495986a4e4072c64dd5c62a56eac.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e943c31ce47a60865af3e28efef64691.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a7b63c6f45ae6c202b0bdbe6bde126e0.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49c9463ec2ff2f6f487029a993e9c72e.webp",980,1301]